

Form for collecting information on

## Collaboration with and support to patient organizations by Orion Pharma companies in 2025

**Czech Republic**

**Zita Skyvova**

Please specify below the ways in which your company has collaborated with patient organizations in your operational territory in 2024. Your local report will be included in Orion's Group-wide summary for 2024 which will be provided publicly at [www.orion.fi/patient-organisation-collaboration](http://www.orion.fi/patient-organisation-collaboration). PO collaboration will also be dealt with in Orion's Corporate Sustainability Report 2024.

In accordance with Article 5 of the currently applicable EFPIA PO Code, the monetary value must be disclosed, without excuses.

Kindly make sure that your local PO collaboration becomes available at your local public website without undue delay.

| Official registered name of the patient organization | Forms of collaboration and support in 2024<br>(specify all forms , bulleted within one cell) | Value in EUR |
|--|--|--------------|
| None   | • None   | 0            |
|  | •  |              |
|  | •  |              |
|  | •  |              |
|  | •  |              |
|  | •  |              |
|  | •  |              |
|  | •  |              |
| Add rows if necessary                                | •  |              |

**Article 5 of the EFPIA patient organisation Code  
Transparency**

a) Each company must make publicly available a list of patient organisations to which it provides financial support and/or significant indirect/non-financial support. This should include a description of the nature of the support that is sufficiently complete to enable the average reader to form an understanding of the significance of the support. The description must include the monetary value of financial support and of invoiced costs. For significant nonfinancial support that cannot be assigned a meaningful monetary value the description must describe clearly the non-monetary benefit that the patient organisation receives. This information may be provided on a national or European level and should be updated at least once a year.<sup>2</sup>

b) Companies must ensure that their sponsorship is always clearly acknowledged and apparent from the outset.

c) Each company must make publicly available a list of patient organisations that it has engaged to provide significant contracted services. This should include a description of the nature of the services provided that is sufficiently complete to enable the average reader to form an understanding of the nature of the arrangement without the necessity to divulge confidential information. Companies must also make public the total amount paid per patient organisation over the reporting period.<sup>3</sup>

The EFPIA Code of Practice on Relationships between the Pharmaceutical Industry and Patient Organisations (The EFPIA Patient Organisation (PO) Code) is accessible at [http://www.efpia-e4ethics.eu/idc/groups/public/documents/códiqodocumento/farma\\_111070.pdf](http://www.efpia-e4ethics.eu/idc/groups/public/documents/códiqodocumento/farma_111070.pdf)